Cite
MLA Citation
Lauretta Odogwu et al.. “FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.” Oncologist, vol. 23, 2018, pp. 353–359. http://access.bl.uk/ark:/81055/vdc_100057585851.0x00001a